Search

727 Result(s)
Sort by

Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Ridgefield Research and Innovation

Ridgefield Research and Innovation

Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
We nurture innovative ideas

We nurture innovative ideas

At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
Data Career

Data Career

Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.
Work life wellness

Work life wellness

We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Ways we’re protecting the planet

Ways we’re protecting the planet

Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
Office Hours Program | Partnering

Office Hours Program | Partnering

Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
Leadership

Leadership

At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Purchasing

Purchasing

Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors